AGO2 and central nervous system cancer: Defuse glioma patients with PTPN1, and AGO2 mutation showed worse overall survival both in the overall group (p = 3.86 × 10−8; Figure 4A) and disease-free/progression-free group (P=2.85 × 10−5; Figure 4B), indicating that PTPN1 and AGO2 may play important roles in diffuse glioma and were related to survival rate.